LEAH MULDOON: Open Payments
NPI 1275145047 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$628 in 27 payments from 11 companies in 2025. Trend: 2023 $747 · 2024 $776 · 2025 $628
Food & beverage: $628
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 5 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $97 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Janssen Biotech, Inc. | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $55 |
| ABBVIE INC. | 3 | $51 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| GENZYME CORPORATION | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
Products named: REZDIFFRA, DUPIXENT, ENTYVIO, TREMFYA, RINVOQ, IQIRVO, ZENPEP, VOQUEZNA.
Industry payments across ID — which companies pay providers there.
